Tumour-derived MVs carrying EGFR/EGFRvIII proteins were successfully detected in patient plasma.Showed four protein panels of EV surface proteins can be used to discriminate GBM patients from healthy controls using novel antibody capture method. The system enabled real-time monitoring of tumour progression and treatment response by tracking changes in circulating tumour-derived MV profiles. This evidence concerns the gene PROS1 and glioblastoma.